ARDS
Aridis Pharmaceuticals, Inc. [ARDS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ARDS Stock Summary
Top 10 Correlated ETFs
ARDS
Top 10 Correlated Stocks
ARDS
In the News
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.
5 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing
Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ARDS Financial details
ARDS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.88 | 0.12 | 0.11 | 0 | 0 | |
| Net income per share | -7.02 | -3.43 | -2.39 | -3.44 | -1.64 | |
| Operating cash flow per share | -7.71 | -0.96 | -2.23 | -1.87 | -1.55 | |
| Free cash flow per share | -7.93 | -0.99 | -2.27 | -1.91 | -1.56 | |
| Cash per share | 7.7 | 2.47 | 0.9 | 1.63 | 0.26 | |
| Book value per share | 8.36 | 0.43 | -0.95 | -1.15 | -1.29 | |
| Tangible book value per share | 8.35 | 0.43 | -0.95 | -1.15 | -1.29 | |
| Share holders equity per share | 8.36 | 0.43 | -0.95 | -1.15 | -1.29 | |
| Interest debt per share | 0.92 | 0 | 0.08 | 0.47 | 0.35 | |
| Market cap | 34.9M | 37.64M | 55.65M | 28.64M | 22.16M | |
| Enterprise value | 10.66M | 16.74M | 48.14M | 14.63M | 23.41M | |
| P/E ratio | -1.58 | -1.3 | -2.54 | -0.68 | -0.72 | |
| Price to sales ratio | 12.66 | 36.83 | 55.65 | 0 | 0 | |
| POCF ratio | -1.44 | -4.61 | -2.72 | -1.25 | -0.76 | |
| PFCF ratio | -1.4 | -4.52 | -2.67 | -1.22 | -0.76 | |
| P/B Ratio | 1.33 | 10.35 | -6.41 | -2.03 | -0.91 | |
| PTB ratio | 1.33 | 10.35 | -6.41 | -2.03 | -0.91 | |
| EV to sales | 3.87 | 16.38 | 48.14 | 0 | 0 | |
| Enterprise value over EBITDA | -0.41 | -0.58 | -2.15 | -0.33 | -0.79 | |
| EV to operating cash flow | -0.44 | -2.05 | -2.35 | -0.64 | -0.8 | |
| EV to free cash flow | -0.43 | -2.01 | -2.31 | -0.62 | -0.8 | |
| Earnings yield | -0.63 | -0.77 | -0.39 | -1.48 | -1.39 | |
| Free cash flow yield | -0.71 | -0.22 | -0.37 | -0.82 | -1.32 | |
| Debt to equity | 0.09 | 0 | -0.08 | -0.42 | -0.25 | |
| Debt to assets | 0.08 | 0 | 0.05 | 0.22 | 0.42 | |
| Net debt to EBITDA | 0.94 | 0.72 | 0.34 | 0.32 | -0.04 | |
| Current ratio | 4.58 | 1.45 | 0.67 | 0.8 | 0.32 | |
| Interest coverage | -57.42 | 0 | 0 | 178.41 | -79.35 | |
| Income quality | 1.1 | 0.27 | 0.92 | 0.54 | 0.96 | |
| Dividend Yield | 0.04 | 0 | 0 | 0.14 | 0 | |
| Payout ratio | -0.06 | 0 | 0 | -0.1 | 0 | |
| Sales general and administrative to revenue | 1.41 | 5.9 | 6.45 | 0 | 0 | |
| Research and developement to revenue | 8.34 | 23.56 | 16.96 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.02 | 0.02 | 0.02 | 0 | |
| Capex to revenue | -0.25 | -0.17 | -0.37 | 0 | 0 | |
| Capex to depreciation | -2.39 | -0.51 | -1.09 | -1.22 | -0.17 | |
| Stock based compensation to revenue | 0.6 | 1.97 | 2.13 | 0 | 0 | |
| Graham number | 36.36 | 5.76 | 7.14 | 9.43 | 6.9 | |
| ROIC | -0.93 | -7.81 | 2.76 | 5.26 | 1.87 | |
| Return on tangible assets | -0.7 | -1.04 | -1.45 | -1.58 | -2.09 | |
| Graham Net | 5.76 | -0.39 | -1.69 | -1.7 | -1.76 | |
| Working capital | 18.94M | 8.64M | -7.32M | -6.55M | -25.27M | |
| Tangible asset value | 26.28M | 3.6M | -8.71M | -14.13M | -24.25M | |
| Net current asset value | 18.94M | 3.64M | -8.68M | -14.11M | -27.3M | |
| Invested capital | 0.09 | 0 | -0.08 | -0.42 | -0.25 | |
| Average receivables | 830K | 1.04M | 390.5K | 302.5K | 738.5K | |
| Average payables | 1.63M | 2.04M | 1.82M | 3.56M | 3.77M | |
| Average inventory | -2.06M | -2.26M | -390.5K | -302.5K | -118.5K | |
| Days sales outstanding | 219.77 | 147.5 | 134.32 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.66 | 2.47 | 2.72 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.84 | -7.97 | 2.52 | 3 | 1.27 | |
| Capex per share | -0.22 | -0.02 | -0.04 | -0.04 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.02 | 0 | 0 | 0 | 0.54 | |
| Net income per share | -0.46 | -0.51 | -0.24 | -0.24 | 0.34 | |
| Operating cash flow per share | -0.35 | -0.24 | -0.39 | -0.13 | -0.12 | |
| Free cash flow per share | -0.35 | -0.24 | -0.39 | -0.13 | -0.12 | |
| Cash per share | 0.36 | 0.11 | 0.22 | 0.04 | 0 | |
| Book value per share | -1.58 | -2.02 | -1.1 | -0.92 | -0.41 | |
| Tangible book value per share | -1.58 | -2.02 | -1.1 | -0.92 | -0.41 | |
| Share holders equity per share | -1.58 | -2.02 | -1.1 | -0.92 | -0.41 | |
| Interest debt per share | 0.73 | 0.79 | 0.23 | 0.13 | 0.17 | |
| Market cap | 19.47M | 16.46M | 25.97M | 9.55M | 7.93M | |
| Enterprise value | 26.15M | 28.66M | 27.22M | 12.18M | 14.21M | |
| P/E ratio | -0.59 | -0.45 | -1.21 | -0.33 | 0.16 | |
| Price to sales ratio | 66.68 | 0 | 0 | 0 | 0.4 | |
| POCF ratio | -3.17 | -3.86 | -3.03 | -2.39 | -1.83 | |
| PFCF ratio | -3.17 | -3.86 | -3.02 | -2.39 | -1.83 | |
| P/B Ratio | -0.7 | -0.46 | -1.07 | -0.34 | -0.53 | |
| PTB ratio | -0.7 | -0.46 | -1.07 | -0.34 | -0.53 | |
| EV to sales | 89.57 | 0 | 0 | 0 | 0.72 | |
| Enterprise value over EBITDA | -3.44 | -3.93 | -3.72 | -1.97 | 1.03 | |
| EV to operating cash flow | -4.26 | -6.72 | -3.18 | -3.04 | -3.27 | |
| EV to free cash flow | -4.25 | -6.72 | -3.16 | -3.04 | -3.27 | |
| Earnings yield | -0.42 | -0.55 | -0.21 | -0.77 | 1.53 | |
| Free cash flow yield | -0.32 | -0.26 | -0.33 | -0.42 | -0.55 | |
| Debt to equity | -0.47 | -0.39 | -0.25 | -0.14 | -0.42 | |
| Debt to assets | 0.78 | 1.16 | 0.42 | 0.42 | 0.97 | |
| Net debt to EBITDA | -0.88 | -1.67 | -0.17 | -0.43 | 0.46 | |
| Current ratio | 0.41 | 0.2 | 0.32 | 0.19 | 0.19 | |
| Interest coverage | -967.13 | 274.52 | 7.18 | -231.96 | 4.56K | |
| Income quality | 0.77 | 0.52 | 1.34 | 0.59 | -0.36 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 5.76 | 0 | 0 | 0 | 0.07 | |
| Research and developement to revenue | 21.74 | 0 | 0 | 0 | 0.24 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | -0.04 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.09 | 0 | -0.49 | 0 | 0 | |
| Stock based compensation to revenue | 1.18 | 0 | 0 | 0 | 0.01 | |
| Graham number | 4.06 | 4.83 | 2.46 | 2.23 | 1.77 | |
| ROIC | 0.62 | 0.41 | 0.38 | 0.3 | -1.94 | |
| Return on tangible assets | -0.49 | -0.75 | -0.36 | -0.78 | 1.88 | |
| Graham Net | -2.1 | -2.59 | -1.51 | -1.18 | -0.59 | |
| Working capital | -18.42M | -33.64M | -25.27M | -28.87M | -16.51M | |
| Tangible asset value | -27.95M | -35.84M | -24.25M | -27.9M | -14.93M | |
| Net current asset value | -31.71M | -39.31M | -27.3M | -30.75M | -17.51M | |
| Invested capital | -0.47 | -0.39 | -0.25 | -0.14 | -0.42 | |
| Average receivables | 992K | 918.5K | 744K | 670K | 200K | |
| Average payables | 2.79M | 3.39M | 3.27M | 3.21M | 5.18M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 489.76 | 0 | 0 | 0 | 1.37 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.18 | 0 | 0 | 0 | 65.49 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.29 | 0.25 | 0.22 | 0.26 | -0.81 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ARDS Frequently Asked Questions
What is Aridis Pharmaceuticals, Inc. stock symbol ?
Aridis Pharmaceuticals, Inc. is a US stock , located in Los gatos of Ca and trading under the symbol ARDS
What is Aridis Pharmaceuticals, Inc. stock quote today ?
Aridis Pharmaceuticals, Inc. stock price is $0.1 today.
Is Aridis Pharmaceuticals, Inc. stock public?
Yes, Aridis Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.63M
- Market Capitalization 4.42M
- Employee 37
- CEO Dr. Vu L. Truong Ph.D.
- Headquarters Los Gatos,CA,US
- IPO Date 2018-08-14
-
Website
https://www.aridispharma.com 
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
